"Long-term" survival in light-chain myeloma with dialysis therapy alone.
We report a case of a 59 year old woman who presented in end-stage renal failure with lambda (lambda) light-chain myeloma (LLCM). Despite a large tumour burden, and refusal to accept cytotoxic chemotherapy, she was commenced on continuous ambulatory peritoneal dialysis (CAPD). With dialysis therapy alone she has shown considerable hematological improvement and remains well 18 months after diagnosis. The extremely poor prognosis attributed to light-chain myeloma is largely due to death from uremia. As the natural history of this disease in patients offered dialysis therapy is unknown, dialysis should not automatically be withheld from patients with LLCM.
D001859:Bone Neoplasms / Q000032:analysis / Q000150:complications*; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000032:analysis*; D007146:Immunoglobulin lambda-Chains / Q000032:analysis*; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000032:analysis / Q000150:complications*; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011379:Prognosis
D007147:Immunoglobulin Light Chains; D007146:Immunoglobulin lambda-Chains